Company: DARE
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001401914-25-000012
Chunk: 50

Company: Dare Bioscience, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 15
Chunk 50
---
 of December 5, 2018 by and among Daré Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC10-K001-3639504/01/201910.10(b)10.7(c)Amendment No. 1 to Assignment Agreement entered into as of December 4, 2019 between Daré Bioscience, Inc. and Hammock Pharmaceuticals, Inc.10-K001-3639503/27/202010.10(c)10.7(d)Amendment No. 2 to the License Agreement entered into as of December 3, 2019 between Daré Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC10-K001-3639503/27/202010.10(d)

136

10.7(e)Amendment to License Agreement effective as of September 21, 2021 by and among Daré Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC10-Q001-3639511/10/202110.110.8+License Agreement dated as of January 10, 2020 between Bayer HealthCare LLC and Daré Bioscience, Inc.10-K001-3639503/27/202010.1610.9+Cooperative Research and Development Agreement entered into as of July 8, 2021 between Daré Bioscience, Inc. and the Eunice Kennedy Shriver National Institutes of Child Health and Human Development Institute10-Q001-3639511/10/202110.210.10+License Agreement dated as of August 12, 2023 between Douglas Pharmaceuticals Limited and Daré Bioscience, Inc.X10.11+Grant Agreement between Daré Bioscience, Inc. and the Bill & Melinda Gates Foundation effective as of June 30, 2021, as amended to dateX10.12+Grant Agreement between Daré Bioscience, Inc. and the Bill & Melinda Gates Foundation effective as of November 11, 2024, as amended to dateX10.13+Subaward Agreement between the Consortium Management Firm, National Collegiate Inventors and Innovators Alliance, Inc. d/b/a/ VentureWell and Daré  Bioscience, Inc., effective as of October 12, 2024X10.14Royalty Interest Financing Agreement entered into as of December 21, 2023 between Dare Bioscience, Inc.